25 items matching your search terms.

Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(>/=3) chemotherapy - The GCIG symptom benefit study (SBS)

Roncolato, F. T. O'Connell, R. L. Joly, F. Lanceley, A. Hilpert, F. Buizen, L. Okamoto, A. Aotani, E. Salutari, V. Donnellan, P. Oza, A. Avall-Lundqvist, E. Berek, J. Fehm, T. Ledermann, J. Roemer-Becuwe, C. Stockler, M. R. King, M. T. Friedlander, M. L.
GYNECOLOGIC ONCOLOGY, 2020     DOI:10.1016/j.ygyno.2019.10.001

PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer

Roncolato, F. Lindemann, K. Willson, M. L. Martyn, J. Mileshkin, L.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2019     DOI:10.1002/14651858.CD012160.pub2

Effect sizes hypothesized and observed in contemporary phase III trials of targeted and immunological therapies for advanced cancer

Lawrence, N. J. Roncolato, F. Martin, A. Simes, R. J. Stockler, M. R.
JNCI CANCER SPECTR, 2018     DOI:10.1093/jncics/pky037

Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS)

Roncolato, F. T. Berton-Rigaud, D. O'Connell, R. Lanceley, A. Sehouli, J. Buizen, L. Okamoto, A. Aotani, E. Lorusso, D. Donnellan, P. Oza, A. Avall-Lundqvist, E. Berek, J. Hilpert, F. Ledermann, J. A. Kaminsky, M. C. Stockler, M. R. King, M. T. Friedlander, M.
GYNECOLOGIC ONCOLOGY, 2018     DOI:10.1016/j.ygyno.2017.10.019

Predictors of stopping chemotherapy early and short survival in patients with potentially platinum sensitive recurrent ovarian cancer who have had ≥3 lines of prior chemotherapy: the GCIG symptom benefit study

Roncolato, F. Joly, F. O'Connell, R.L. Lanceley, A. Heitz, F. Buizen, L. Okamato, A. Aotani, E. Salutari, V. Donnellan, P.P. Oza, A.M. Avall-Lundqvist, E. Berek, J.S. Hilpert, F. Feeney, A. Roemer-Becuwe, C. Stockler, M.R. King, M.T. Friedlander, M. GCIG Symptom Benefit Study Group,

Reducing uncertainty: Predictors of stopping chemotherapy early and shortened survival time in platinum resistant/refractory ovarian cancer-the GCIG symptom benefit study

Roncolato, F. T. Joly, F. O'Connell, R. Lanceley, A. Hilpert, F. Buizen, L. Okamoto, A. Aotani, E. Pignata, S. Donnellan, P. Oza, A. Avall-Lundqvist, E. Berek, J. S. Heitz, F. Feeney, A. Berton-Rigaud, D. Stockler, M. R. King, M. Friedlander, M. Gcig Symptom Benefit group
ONCOLOGIST, 2017     DOI:10.1634/theoncologist.2017-0047

Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy

Roncolato, F. T. Gibbs, E. Lee, C. K. Asher, R. Davies, L. C. Gebski, V. J. Friedlander, M. Hilpert, F. Wenzel, L. Stockler, M. R. King, M. Pujade-Lauraine, E.
ANNALS OF ONCOLOGY, 2017     DOI:10.1093/annonc/mdx229

Current clinician practices in utilizing radiotherapy and molecularly targeted therapies in treating patients with metastatic renal cell carcinoma: an ANZUP SURVEY

Chan, H. Roncolato, F. Long, A. Foroudi, F. Goldstein, D. Siva, S. Davis, I.

The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study

He, E. Y. Hawkins, N. J. Mak, G. Roncolato, F. Goldstein, D. Liauw, W. Clingan, P. Chin, M. Ward, R. L.
ONCOLOGIST, 2016     DOI:10.1634/theoncologist.2015-0530

Effect sizes hypothesized in phase 3 trials published from 2005 to 2015 versus recommendations of the ASCO working party on clinically meaningful outcomes

Lawrence, N. Roncolato, F. Stockler, M. R.

Valuing the effect sizes hypothesized in phase 3 trials published from 2005 to 2015

Lawrence, N. Roncolato, F. Stockler, M

PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer

Martyn, Julie Roncolato, Felicia Willson, Melina L. Lindemann, Kristina Mileshkin, Linda
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016     DOI:10.1002/14651858.Cd012160

Quality of life to predict overall survival in women with platinum-resistant ovarian cancer

Roncolato, F Gibbs, E. Lee, C. Davies, L.C. Gebski, V. Friedlander, M. Hilpert, F. Wenzel, L.B. Stockler, M.R. King, M.T. Pujade-Lauraine, E

Baseline quality of life as a predictor of stopping chemotherapy early, and of overall survival, in platinum-resistant/refractory ovarian cancer: the GCIG Symptom Benefit study

Roncolato, F. O'Connell, R.O. Buizen, L. Joly, F. Lanceley, A. Hilpert, F. Okamoto, A. Aotani, E. Pignata, S Donnellan, P.P. Oza, A.M. Avall-Lundqvist, E. Berek, J.S. Sjoquist, K.M. Gillies, K. Stockler, M.R. King, M.T. Friedlander, M. GCIG Symptom Benefit Study Group,

The effect of pulmonary function testing on bleomycin dosing in germ cell tumours

Roncolato, F. T. Chatfield, M. Houghton, B. Toner, G. Stockler, M. Thomson, D. Friedlander, M. Gurney, H. Rosenthal, M. Grimison, P. Australian, New Zealand Urogenital Prostate Cancer Trials, Group
INTERNAL MEDICINE JOURNAL, 2016     DOI:10.1111/imj.13158